Back to Search
Start Over
No increased risk of breast or gynecologic malignancies in women exposed to spironolactone for dermatologic conditions: A retrospective cohort study.
- Source :
-
Journal of the American Academy of Dermatology [J Am Acad Dermatol] 2024 Jun; Vol. 90 (6), pp. 1302-1304. Date of Electronic Publication: 2024 Feb 27. - Publication Year :
- 2024
-
Abstract
- Competing Interests: Conflicts of interest Dr Lipner has served as a consultant for Ortho-Dermatologics, Eli Lilly, Moberg Pharmaceuticals, and BelleTorus Corporation. Author Hill, Dr Wang, and Author Shaikh have no conflicts of interest to declare.
- Subjects :
- Humans
Female
Retrospective Studies
Middle Aged
Adult
Aged
Risk Assessment
Mineralocorticoid Receptor Antagonists adverse effects
Mineralocorticoid Receptor Antagonists therapeutic use
Cohort Studies
Breast Neoplasms drug therapy
Spironolactone adverse effects
Spironolactone therapeutic use
Genital Neoplasms, Female epidemiology
Skin Diseases chemically induced
Skin Diseases epidemiology
Subjects
Details
- Language :
- English
- ISSN :
- 1097-6787
- Volume :
- 90
- Issue :
- 6
- Database :
- MEDLINE
- Journal :
- Journal of the American Academy of Dermatology
- Publication Type :
- Editorial & Opinion
- Accession number :
- 38423468
- Full Text :
- https://doi.org/10.1016/j.jaad.2024.02.030